Press release BoxID: 632804 (Xenios AG)
  • Xenios AG
  • Im Zukunftspark 1
  • 74076 Heilbronn

Novalung Moves Production Facility

Manufacturing and Company Headquarters Are Now Under One Roof

(PresseBox) (Heilbronn, ) Novalung GmbH's new production facility was officially inaugurated by its Managing Directors, Josef Bogenschütz und Dr. Georg Matheis, during a small party on September 12. Following the move of the company's headquarters to the Heilbronn Technology and Future Park "Wohlgelegen" in October 2010, the production facility has now also been moved from Oberstenfeld to the headquarters location.

After a planning and construction phase of nearly two years, the production facility with a total work area of 1200 m² was put into service in August. The new production area boasts a 500 m² ISO Class 7 clean room and meets all of the requirements of the US GMP (Good Manufacturing Practice) standard. The clean room is fitted with state-of-the-art "real-time" monitoring, a so-called visualization system that controls the air in the clean room. The state-of-the-art technical control center ensures that the room humidity is optimized for energy efficiency. Rounding out the new facility are well-equipped laboratories and workshops and an optimized logistics and warehousing are for successful material flow.

The move is indicative of Novalung's continued growth. The clean-room manufacturing for medical devices, which was originally located in Hechingen, moved into a larger production facility near Heilbronn in 2009. The current move, too, was intended to increase the production capacity and finally bring administration and manufacturing under one roof. The new production facility not only offers state-of-the-art technology, but also optimal conditions for modern and attractive workplaces in a dynamic company.

Website Promotion

Xenios AG

Novalung GmbH is a leading international medical device company with headquarters in Heilbronn, Germany. Novalung has been developing and manufacturing products for interventional lung assist (iLA®) therapy in Germany since 2003 and is today the first to offer a complete product portfolio for extrapulmonary lung support. Whatever form of extrapulmonary lung support is required, Novalung can offer a tailor-made solution, from effective removal of carbon dioxide to complete oxygenation support, for new-born infants through to adults. A broad technology base, extensive clinical experience, specialized know-how and outstanding motivation guarantee the consistently high quality of Novalung products. Working together with leading users, the company has continuously advanced Novalung's technologies to develop iLA® therapy as an alternative to invasive ventilation, and as such has initiated a paradigm shift in the treatment of lung failure. Following a clear focus on the further development of iLA® therapy to pioneer novel solutions for acute and chronic lung failure, the company remains on track for continued expansion. From our manufacturing sites across Germany we deliver solutions for lung failure throughout the world.For more information, please visit: